The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Enhancing immunotherapy for CLL patients with ibrutinib
Meixiao Long, MD from the Ohio State University, Columbus, OH discusses his work on immune modulating therapies for chronic lymphocytic leukemia (CLL) at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY. His work is based on modulating T-cell immunity to essentially improve T-cell immunotherapy. Dr Long highlights some of his findings from his study on ibrutinib. His main finding is how ibrutinib can promote persistence of T-cells. This finding is not of any significance on its own. However if ibrutinib is combined with for e.g. tumour targeting T-cells such as CAR T-cells, it could definitely enhance the effect of this mode of immunotherapy and many others.
